company background image
2197 logo

Clover Biopharmaceuticals SEHK:2197 Stock Report

Last Price

HK$0.41

Market Cap

HK$538.2m

7D

-1.2%

1Y

-75.3%

Updated

27 Mar, 2024

Data

Company Financials

Clover Biopharmaceuticals, Ltd.

SEHK:2197 Stock Report

Market Cap: HK$538.2m

2197 Stock Overview

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates.

2197 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Clover Biopharmaceuticals, Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clover Biopharmaceuticals
Historical stock prices
Current Share PriceHK$0.41
52 Week HighHK$2.04
52 Week LowHK$0.39
Beta3.92
1 Month Change-5.68%
3 Month Change-29.66%
1 Year Change-75.30%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.80%

Recent News & Updates

Recent updates

Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth

Mar 17
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth

Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?

Nov 29
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?

Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?

Aug 31
Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?

We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely

Apr 28
We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely

Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate

Feb 05
Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate

Shareholder Returns

2197HK BiotechsHK Market
7D-1.2%-3.3%0.3%
1Y-75.3%-41.9%-12.7%

Return vs Industry: 2197 underperformed the Hong Kong Biotechs industry which returned -41.9% over the past year.

Return vs Market: 2197 underperformed the Hong Kong Market which returned -12.7% over the past year.

Price Volatility

Is 2197's price volatile compared to industry and market?
2197 volatility
2197 Average Weekly Movement8.8%
Biotechs Industry Average Movement9.9%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 2197's share price has been volatile over the past 3 months.

Volatility Over Time: 2197's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007681Joshua G. Lianghttps://www.cloverbiopharma.com

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform.

Clover Biopharmaceuticals, Ltd. Fundamentals Summary

How do Clover Biopharmaceuticals's earnings and revenue compare to its market cap?
2197 fundamental statistics
Market capHK$538.23m
Earnings (TTM)-HK$720.16m
Revenue (TTM)HK$278.24k

1,934x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2197 income statement (TTM)
RevenueCN¥257.00k
Cost of RevenueCN¥1.72b
Gross Profit-CN¥1.72b
Other Expenses-CN¥1.05b
Earnings-CN¥665.19m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin-669,157.20%
Net Profit Margin-258,830.35%
Debt/Equity Ratio1,435.8%

How did 2197 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.